| Total (N=226) | Group 1 (N=49) | Group 2 (N=80) | Group 3 (N=20) | Group 4 (N=77) | P value |
---|---|---|---|---|---|---|
State, N (%) | Â | Â | Â | Â | Â | 0.004 |
 IL | 153 (67.7) | 35 (71.4) | 61 (76.3) | 16 (80.0) | 41 (53.3) |  |
 IN | 51 (22.6) | 12 (24.5) | 15 (18.7) | 2 (10.0) | 22 (28.6) |  |
 WI | 22 (9.7) | 2 (4.1) | 4 (5.0) | 2 (10.0) | 14 (18.2) |  |
Wave | Â | Â | Â | Â | Â | 0.81 |
 1 | 42 (18.6) | 9 (18.4) | 14 (17.5) | 4 (20.0) | 15 (19.5) |  |
 2 | 40 (17.7) | 9 (18.4) | 16 (20.0) | 4 (20.0) | 11 (14.3) |  |
 3 | 67 (29.7) | 10 (20.4) | 21 (26.3) | 6 (30.0) | 30 (39.0) |  |
 4 | 77 (34.1) | 21 (42.9) | 29 (36.3) | 6 (30.0) | 21 (27.3) |  |
Number of clinicians, N (%) | Â | Â | Â | Â | Â | 0.95 |
 Solo | 89 (39.4) | 19 (38.8) | 34 (42.5) | 8 (40.0) | 28 (36.4) |  |
 2–5 | 116 (51.3) | 24 (49.0) | 38 (47.5) | 9 (45.0) | 45 (58.4) |  |
 6–10 | 19 (8.4) | 4 (8.2) | 8 (10.0) | 3 (15.0) | 4 (5.2) |  |
 11–15 | 2 (0.9) | 2 (4.1) | 0 | 0 | 0 |  |
Network, N (%) | Â | Â | Â | Â | Â | 0.76 |
 Yes | 76 (33.6) | 21 (42.9) | 28 (35.0) | 6 (30.0) | 21 (27.3) |  |
 No | 150 (66.4) | 28 (57.1) | 52 (65.0) | 14 (70.0) | 56 (72.7) |  |
FQHC, N (%) | Â | Â | Â | Â | Â | 0.96 |
 Yes | 64 (28.3) | 16 (32.7) | 24 (30.0) | 5 (25.0) | 19 (24.7) |  |
 No | 162 (71.7) | 33 (67.4) | 56 (70.0) | 15 (75.0) | 58 (75.3) |  |
Visits, median (IQR) | 5 (3–8) | 3 (1–4) | 4 (3–5) | 8 (5–9.5) | 8 (7–10) | < 0.001 |
Duration, median (IQR) | 305 (165–495) | 120 (90–188) | 250 (150–338) | 373 (280–773) | 455 (330–630) | < 0.001 |
Completed study | Â | Â | Â | Â | Â | < 0.001 |
 Yes | 213 (94.3) | 40 (81.6) | 77 (96.3) | 20 (100.0) | 76 (98.7) |  |
 No | 13 (5.7) | 9 (18.4) | 3 (3.75) | 0 | 1 (1.3) |  |